Skip to search formSkip to main contentSkip to account menu

ARRY 520

Known as: ARRY-520, KSP Inhibitor ARRY-520 
A synthetic, small molecule targeting the kinesin spindle protein (KSP) with potential antineoplastic activity. KSP inhibitor ARRY-520 specifically… 
National Institutes of Health

Related topics

Related topics

5 relations
KIF11 protein, humanNCIt Antineoplastic Agent TerminologyNegative Regulation of Cell CyclePositive Regulation of Apoptosis

Broader (1)

Thiadiazoles

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Prolonged Survival and Improved Response Rates With ARRY-520 In Relapsed/Refractory Multiple Myeloma (RRMM) Patients With Low α-1 Acid Glycoprotein (AAG) Levels: Results From a Phase 2 Study
Background The availability of multiple immunomodulators (IMiDs) and proteasome inhibitors (PIs) has resulted in improved… 
2013
2013
A Phase 1 Study Of ARRY-520 With Bortezomib (BTZ) and Dexamethasone (dex) In Relapsed Or Refractory Multiple Myeloma (RRMM)
Background ARRY-520 is a novel KSP inhibitor with encouraging activity in patients (pts) with RRMM. In preclinical models, the… 
2013
2013
ARRY-520 Combined With Pomalidomide Displays Enhanced Anti-Tumor Activity In Preclinical Models Of Multiple Myeloma
Inhibitors of Kinesin Spindle Protein (KSP), a mitosis-specific motor protein, represent a novel class of targeted anti-cancer… 
Review
2013
Review
2013
Novel approaches to treatment of double-refractory multiple myeloma.
Multiple myeloma (MM) refractory to both proteasome inhibitors and immunomodulatory agents (IMiDs; double-refractory myeloma) has… 
2012
2012
Identification of Alpha 1-Acid Glycoprotein (AAG) As a Potential Patient Selection Biomarker for Improved Clinical Activity of the Novel KSP Inhibitor ARRY-520 in Relapsed and Refractory Multiple…
Abstract 1868 Background ARRY-520 is a kinesin spindle protein (KSP) inhibitor that has demonstrated clinical activity in… 
2011
2011
The Novel KSP Inhibitor ARRY-520 Demonstrates Single-Agent Activity in Refractory Myeloma: Results From a Phase 2 Trial in Patients with Relapsed/Refractory Multiple Myeloma (MM)
Abstract 2935 Background: ARRY-520 is a potent, selective inhibitor of kinesin spindle protein (KSP, eg5) which is required for… 
2010
2010
A Phase I/II Trial of the KSP Inhibitor ARRY-520 In Relapsed/Refractory Multiple Myeloma
Abstract 1959 Background: Kinesin Spindle Protein (KSP) is required for cell cycle progression through mitosis. Inhibition of KSP… 
2010
2010
Phase I trial of ARRY-520 in relapsed/refractory multiple myeloma (RR MM).
8132 Background: Kinesin Spindle Protein (KSP) is required for cell cycle progression through mitosis. ARRY-520 is a potent… 
2009
2009
A phase I dose-escalation study of the novel KSP inhibitor ARRY-520 in advanced leukemias.
7022 ARRY-520 is a potent, selective KSP inhibitor that arrests cells in mitosis with the subsequent onset of apoptosis. ARRY-520… 
2009
2009
T cells helping GVHD: take-away lessons.
Using double cytokine knockout donor CD4 cells, in this issue of Blood , Yi and colleagues help clarify the complex role of IFN… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)